78967-81-4

Basic information

• Product Name: 2-Bromo-1-(2,4-dichlorophenyl)butan-1-one
• Synonyms: 2-Bromo-1-(2,4-dichlorophenyl)butan-1-one
• CAS NO: 78967-81-4
• Molecular Formula: C₁₀H₉BrCl₂O
• Molecular Weight: 295.98786
• Mol File: 78967-81-4.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 320.117 °C at 760 mmHg
• Flash Point: 147.402 °C
• Appearance: /
• Density: 1.546 g/cm³
• CAS DataBase Reference: 2-Bromo-1-(2,4-dichlorophenyl)butan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-1-(2,4-dichlorophenyl)butan-1-one(78967-81-4)
• EPA Substance Registry System: 2-Bromo-1-(2,4-dichlorophenyl)butan-1-one(78967-81-4)

Safety Data

• Hazardous Substances Data: 78967-81-4(Hazardous Substances Data)

Usage

General Description

2-Bromo-1-(2,4-dichlorophenyl)butan-1-one, also known as Bromadol, is a synthetic narcotic analgesic of the opioid and sedative drug classes. It was first patented in 1978 and is similar in structure to the more well-known drug, fentanyl. Bromadol is an extremely potent opioid, with a reported potency thousands of times greater than that of morphine. It has an analgesic potency that is approximately 10,000 times that of morphine and has been found to produce prolonged and profound analgesia in animal studies. Due to its high potency and potential for abuse, as well as its lack of approved medical use, Bromadol is classified as a Schedule I controlled substance in the United States.

Upstream product

• 66353-47-7 1-(2,4-dichlorophenyl)butan-1-one 

Relevant articles and documents

Synthesis and biological activity evaluation of 1,2,3-thiadiazole derivatives as potential elicitors with highly systemic acquired resistance

Elicitors provide a broad spectrum of systemic acquired resistance by altering the physical and physiological status of the host plants and, therefore, are among the most successful directions in modern pesticide development for plant protection. To develop a novel elicitor with highly systemic acquired resistance, two series of thiazole- and oxadiazole-containing thiadiazole derivatives were rationally designed and synthesized according to the principle of combination of bioactive substructures in this work. Their structures were characterized by 1H nuclear magnetic resonance (NMR), infrared (IR), high-resolution mass spectrometry (HRMS), or elemental analysis. Their potential systemic acquired resistance as an elicitor was also evaluated; bioassay results indicated that, among the 23 compounds synthesized, three compounds, 10a, 10d, and 12b, displayed better systemic acquired resistance than the positive control, tiadinil, a commercialized 1,2,3-thiadiazolebased elicitor. In addition, three other compounds, 10f, 12c, and 12j, exhibited a certain degree of fungus growth inhibition In vitro or In vivo. Our results demonstrated that, in combination of bioactive substructures is an interesting exploration for novel pesticide development, thiazole-and oxadiazole-containing thiadiazole derivatives are potential elicitors with good systemic acquired resistance.